Skip to main content
main-content

Rheumatoid arthritis

Medications

19-03-2019 | Rheumatoid arthritis | News

Almost half of RA patients relapse after TNF inhibitor discontinuation

Findings from a systematic review and meta-analysis suggest that nearly half of patients with rheumatoid arthritis in remission experience disease relapse after elective discontinuation of tumor necrosis factor inhibitors.

11-03-2019 | Rheumatoid arthritis | News

No impact of comorbidities on efficacy, safety profiles of baricitinib in RA patients

Findings from a post-hoc pooled analysis suggest that comorbidity does not influence the efficacy or safety of baricitinib 4 mg once daily in patients with rheumatoid arthritis who have had an inadequate response to conventional DMARDs.

08-03-2019 | Rheumatoid arthritis | News

Consensus guidelines for management of comorbid RA, cancer examined

A systematic review of consensus recommendations for the management of rheumatoid arthritis in patients with cancer shows agreement in some areas, but highlights the need for further research into topics for which discrepancies exist.

07-03-2019 | Rheumatoid arthritis | News

Support for sarilumab combination therapy in pretreated RA

Findings from a systematic review and network meta-analysis indicate that adding sarilumab to conventional DMARDs may be beneficial for patients with rheumatoid arthritis and an inadequate response to either conventional DMARDs or tumor necrosis factor inhibitors.

05-03-2019 | Rheumatoid arthritis | News

FDA issues tofacitinib safety alert

The US FDA warns that treatment with the Janus kinase inhibitor tofacitinib at a dose of 10 mg twice daily is associated with an increased risk for pulmonary embolism and death in patients with rheumatoid arthritis.

22-02-2019 | Adalimumab biosimilar | News

EMA gives nod to two adalimumab biosimilars

The Committee for Medicinal Products for Human Use has recommended two new adalimumab biosimilars for approval in Europe.

19-02-2019 | Rheumatoid arthritis | News

Durable efficacy of tofacitinib in RA patients demonstrated

Patients with rheumatoid arthritis who are treated with the Janus kinase inhibitor tofacitinib alongside methotrexate experience sustained efficacy for up to 2 years, suggest follow-up results from the phase III ORAL Scan study.

18-02-2019 | Rheumatoid arthritis | News

No benefit of prolonged abatacept cessation before joint replacement in RA patients

Among patients with rheumatoid arthritis undergoing elective joint replacement, stopping intravenous abatacept treatment for more than one dosing interval prior to surgery may not result in better postoperative outcomes than a shorter length of discontinuation, researchers report.

11-02-2019 | Rheumatoid arthritis | News

Tocilizumab linked to elevated risk for some types of infection

Findings from a multi-database study suggest that rheumatoid arthritis patients treated with tocilizumab do not have a higher overall risk for serious infection than those treated with tumor necrosis factor inhibitors, but their risk for certain types of infection may be elevated.

11-02-2019 | Rheumatoid arthritis | Editorial | Article

20 years of TNF inhibitors in rheumatoid arthritis

Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

20 years of TNF inhibitors in rheumatoid arthritis

Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

Effectiveness of tocilizumab, rituximab over other biologics demonstrated

Patients with rheumatoid arthritis have better outcomes when treated with rituximab or tocilizumab than abatacept or tumor necrosis factor inhibitors, suggest the results from two real-world studies.

31-01-2019 | Rheumatoid arthritis | Highlight | News

Effectiveness of tocilizumab, rituximab over other biologics demonstrated

Patients with rheumatoid arthritis have better outcomes when treated with rituximab or tocilizumab than abatacept or tumor necrosis factor inhibitors, suggest the results from two real-world studies.

23-01-2019 | Rheumatoid arthritis | News

Hydroxychloroquine may benefit some RA patients if combined with other drugs

Hydroxychloroquine may offer a degree of clinical benefit to patients with rheumatoid arthritis when used in combination with conventional synthetic DMARDs, suggest the results of a systematic review.

Gene expression profiling points to methotrexate nonresponders

Rheumatoid arthritis patients who are unlikely to respond to methotrexate could be identified based on their gene expression profiles before and 4 weeks after initiating treatment, say researchers.

16-01-2019 | Rheumatoid arthritis | Highlight | News

Gene expression profiling points to methotrexate nonresponders

Rheumatoid arthritis patients who are unlikely to respond to methotrexate could be identified based on their gene expression profiles before and 4 weeks after initiating treatment, say researchers.

10-01-2019 | Rheumatoid arthritis | News

Biologic combination therapy for RA may increase risk for side effects

Findings from a systematic review and meta-analysis suggest that rheumatoid arthritis patients who receive combination therapy with two biologic DMARDs are more likely to experience adverse events than those given one biologic.

09-01-2019 | Rheumatoid arthritis | News

Serious infection risk similar among non-TNF inhibitor biologics in RA

Study findings do not support the use of one non-tumor necrosis factor inhibitor biologic DMARD over another when considering the risk for serious infection in patients with rheumatoid arthritis.

07-01-2019 | Rheumatoid arthritis | News

Abatacept associated with lower serious infection risk than TNF inhibitors

Rheumatoid arthritis patients who are treated with abatacept have a lower risk for hospitalization due to infection than those given tumor necrosis factor inhibitors, findings from a real-world study suggest.

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

image credits